A 58-year-old man with stage 4 CKD (eGFR 22 mL/min/1.73 m²) presents for routine follow-up. Laboratory investigations show: hemoglobin 8.2 g/dL, serum creatinine 3.8 mg/dL, phosphate 5.2 mg/dL, calcium 7.8 mg/dL (corrected), PTH 285 pg/mL. Regarding the management of anemia in this patient, all of the following are correct EXCEPT:

Question

Accepted Answer

A. ESAs can be safely used as monotherapy without concurrent phosphate binders or PTH-lowering agents in stage 4 CKD with secondary hyperparathyroidism. ## Management of Anemia in CKD: Integrated Approach

### The Incorrect Statement
**Key Point:** ESAs are NOT monotherapy for CKD anemia. Anemia in CKD is multifactorial and occurs alongside mineral bone disorder. Using ESAs alone without addressing secondary hyperparathyroidism, hyperphosphatemia, and hypocalcemia is incomplete and potentially harmful. Uncontrolled PTH and phosphate increase cardiovascular risk and worsen anemia responsiveness.

### Integrated Management Framework

```mermaid
flowchart TD
  A[Stage 4 CKD + Anemia]:::outcome --> B[Assess iron stores]:::decision
  B -->|Iron deficient| C[Repleted iron]:::action
  B -->|Iron replete| D[Initiate ESA]:::action
  A --> E[Assess mineral metabolism]:::decision
  E -->|Hyperphosphatemia| F[Phosphate binders]:::action
  E -->|High PTH| G[Calcitriol/Cinacalcet]:::action
  E -->|Hypocalcemia| H[Calcium supplementation]:::action
  C --> D
  F --> I[Integrated CKD-MBD management]:::outcome
  G --> I
  H --> I
  D --> I
```

### Why the Other Statements Are Correct

| Statement | Evidence | Citation |
|-----------|----------|----------|
| Iron repletion before ESA | Iron is essential cofactor for erythropoiesis; iron deficiency reduces ESA responsiveness | KDIGO 2021 |
| Target Hb 10–12 g/dL; avoid >13 g/dL | Trials (CREATE, CHOIR) show increased CV events and mortality with Hb >13 g/dL; target is individualized but generally 10–12 | KDIGO 2021 |
| IV iron preferred in dialysis | IV iron bypasses GI absorption issues, achieves faster repletion, and is standard in dialysis population | KDIGO 2021 |

**High-Yield:** The KDIGO 2021 anemia guideline emphasizes that ESA therapy must be integrated with mineral bone disorder management. Uncontrolled secondary hyperparathyroidism impairs erythropoiesis and increases mortality independent of hemoglobin level.

**Clinical Pearl:** In this patient, management should include: (1) iron assessment and repletion if needed, (2) ESA initiation targeting Hb 10–12 g/dL, (3) phosphate binder (e.g., calcium acetate or non-calcium binder), (4) calcitriol or cinacalcet for PTH control, and (5) calcium supplementation if hypocalcemic. All four interventions are necessary — not ESA monotherapy.

**Warning:** Isolated ESA therapy without addressing mineral bone disorder is associated with worse outcomes and increased cardiovascular mortality in CKD patients.

[cite:KDIGO 2021 Anemia Guideline; Harrison 21e Ch 279]

Answer

B. Erythropoiesis-stimulating agents (ESAs) should be initiated only after iron stores have been repleted and iron deficiency has been excluded

Answer

C. Intravenous iron should be preferred over oral iron in dialysis patients due to superior efficacy and reduced gastrointestinal side effects

Answer

D. Target hemoglobin should be maintained between 10–12 g/dL; hemoglobin >13 g/dL is associated with increased cardiovascular events and mortality

Explanation

Practice similar questions